Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial

EClinicalMedicine ◽

10.1016/j.eclinm.2021.101261 ◽

2022 ◽

Vol 43 ◽

pp. 101261

Author(s):

Kim M. Huffman ◽

Daniel C. Parker ◽

Manjushri Bhapkar ◽

Susan B. Racette ◽

Corby K. Martin ◽

...

Keyword(s):

Risk Factors ◽

Calorie Restriction ◽

Cardiometabolic Risk ◽

Controlled Trial ◽

Healthy Adults ◽

Cardiometabolic Risk Factors ◽

Phase 2 ◽

Multicentre Phase ◽

2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30151-2 ◽

2019 ◽

Vol 7 (9) ◽

pp. 673-683 ◽

Cited By ~ 45

Author(s):

William E Kraus ◽

Manjushri Bhapkar ◽

Kim M Huffman ◽

Carl F Pieper ◽

Sai Krupa Das ◽

...

Keyword(s):

Calorie Restriction ◽

Cardiometabolic Risk ◽

Controlled Trial ◽

Phase 2 ◽

Multicentre Phase ◽

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30326-2 ◽

2019 ◽

Vol 20 (8) ◽

pp. 1148-1159 ◽

Cited By ~ 65

Author(s):

Sylvie Bonvalot ◽

Piotr L Rutkowski ◽

Juliette Thariat ◽

Sébastien Carrère ◽

Anne Ducassou ◽

...

Keyword(s):

Hafnium Oxide ◽

Controlled Trial ◽

Locally Advanced ◽

Phase 2 ◽

Advanced Soft Tissue Sarcoma ◽

Multicentre Phase ◽

Radiotherapy Alone ◽

Oxide Nanoparticle ◽

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

The Lancet Haematology ◽

10.1016/s2352-3026(19)30114-0 ◽

2019 ◽

Vol 6 (9) ◽

pp. e480-e488 ◽

Cited By ~ 19

Author(s):

Farhad Ravandi ◽

Rita Assi ◽

Naval Daver ◽

Christopher B Benton ◽

Tapan Kadia ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30210-6 ◽

2020 ◽

Vol 7 (10) ◽

pp. e724-e736 ◽

Cited By ~ 7

Author(s):

Courtney D DiNardo ◽

Abhishek Maiti ◽

Caitlin R Rausch ◽

Naveen Pemmaraju ◽

Kiran Naqvi ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Centre ◽

Phase 2 Trial ◽

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00494-0 ◽

2021 ◽

Author(s):

Courtney D DiNardo ◽

Andre C Schuh ◽

Eytan M Stein ◽

Pau Montesinos ◽

Andrew H Wei ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Trial ◽

Phase 1B ◽

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(18)30182-0 ◽

2019 ◽

Vol 6 (1) ◽

pp. e29-e37 ◽

Cited By ~ 27

Author(s):

Nicholas J Short ◽

Hagop M Kantarjian ◽

Sanam Loghavi ◽

Xuelin Huang ◽

Wei Qiao ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Older Patients ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Trial ◽

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30151-2 ◽

2019 ◽

Vol 20 (7) ◽

pp. 948-960 ◽

Cited By ~ 74

Author(s):

Elisa A Rozeman ◽

Alexander M Menzies ◽

Alexander C J van Akkooi ◽

Chandra Adhikari ◽

Carolien Bierman ◽

...

Keyword(s):

Controlled Trial ◽

Optimal Combination ◽

Stage Iii ◽

Phase 2 ◽

Dosing Schedule ◽

Multicentre Phase ◽

Stage Iii Melanoma ◽

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00247-6 ◽

2021 ◽

Vol 397 (10282) ◽

pp. 1363-1374 ◽

Cited By ~ 1

Author(s):

Anthony Marson ◽

Girvan Burnside ◽

Richard Appleton ◽

Dave Smith ◽

John Paul Leach ◽

...

Keyword(s):

Cost Effectiveness ◽

Focal Epilepsy ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00246-4 ◽

2021 ◽

Vol 397 (10282) ◽

pp. 1375-1386 ◽

Cited By ~ 1

Author(s):

Anthony Marson ◽

Girvan Burnside ◽

Richard Appleton ◽

Dave Smith ◽

John Paul Leach ◽

...

Keyword(s):

Cost Effectiveness ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Multicentre Phase ◽